Disinfection Systems in Washington

HealthFirst is a FDA-registered and DEA-licensed supplier of medical emergency preparedness products and healthcare compliance solutions, serving over 65,000 medical and dental facilities since 1969. The company specializes in STAT KIT® emergency medical kits in multiple configurations (SM5, SM7, SM10, SM27, SM30, 550, 550-AI, 750, 750-AI, Z-1000 Mobile ACLS), unit-dose emergency medications (including cardiac, hemostatic, and anesthetic agents), infection control products (dental waterline testing, spore testing, antimicrobial treatments), and medical waste management solutions (sharps disposal, pharmaceutical waste recovery, amalgam separation). HealthFirst's OnTraq™ platform provides smart automation for practice insights, document storage, employee task assignment, and regulatory compliance tracking. The company is accredited by the National Association of Boards of Pharmacy and DSCSA-compliant. Services include OSHA and HIPAA training, compliance documentation support, and waste management programs for dental, medical, public access, and government facilities, supporting emergency preparedness and clinical safety across multiple healthcare settings.

Magnolia Medical Technologies develops diagnostic solutions focused on reducing blood culture contamination and improving sepsis diagnostic accuracy. The company's flagship product is the Steripath® Micro Initial Specimen Diversion Device®, an FDA 510(k)-cleared device designed to reduce false-positive blood culture results in sepsis testing. The Steripath Platform is offered in two configurations: Steripath Micro for Direct to Media and Steripath Micro for Syringe Draws, supporting both peripheral venipuncture and peripheral IV start collection methods. Clinical studies demonstrate 83–88% contamination rate reduction depending on collection method. The device addresses a critical clinical challenge: blood culture contamination and misdiagnosis lead to unnecessary broad-spectrum antibiotic use, driving antibiotic resistance, Clostridioides difficile infections, and an estimated $6 billion in annual U.S. healthcare waste. Magnolia's platform is trusted by major hospital systems and health networks including Ascension, Premier, Cardinal Health, VA, Vizient, and HealthTrust, with clinical validation published in peer-reviewed journals including Clinical Infectious Diseases, Journal of Hospital Infection, and American Journal of Medical Quality. The company emphasizes diagnostic stewardship and quality outcomes improvement, with recognition from Newsweek for infection prevention innovation.

NorMed is a premier B2B distributor of first aid and immediate care medical supplies, established in 1974 and based in Seattle, Washington. The company serves industrial, hospitality, recreational, and employee healthcare sectors with a comprehensive product portfolio including first aid kits, wound care supplies, infection control products, EMS and trauma kits, gauze products, adhesive bandages, cohesive wraps, burn relief items, topical treatments, eye wash stations, and over-the-counter medications. NorMed emphasizes regulatory compliance and quality assurance across its curated selection of branded products. With approximately 82 employees and $32.1 million in annual revenue, the distributor operates nationwide serving businesses and government entities. The company is known for competitive pricing, broad product selection, quick order fulfillment with high fill rates, and responsive customer support.

Ondine Biomedical Inc. is a Canadian life sciences company specializing in photodisinfection (antimicrobial photodynamic therapy) technologies for infection prevention and treatment. The company's patented platform uses non-thermal laser light activation with photosensitive agents to destroy bacteria, viruses, yeasts, fungi, and associated virulence factors within minutes—without generating antimicrobial resistance. The lead product, Steriwave, is a rapid nasal decolonization therapy that eliminates broad-spectrum pathogens including methicillin-resistant Staphylococcus aureus (MRSA), Candida auris, and SARS-CoV-2 from the nasal cavity, significantly reducing healthcare-associated infections (HAIs) and surgical site infections (SSIs). Clinical evidence from major Canadian hospitals demonstrates up to 84% reduction in postoperative infection rates and 39.5% pneumonia reduction in ICU settings. Photodisinfection offers advantages over traditional antibiotics including immediate pathogen destruction, potent anti-inflammatory effects, and safety for patient outcomes. The company maintains a pipeline of investigational products addressing chronic rhinosinusitis, burn and wound decolonization, endotracheal tube disinfection to prevent ventilator-associated pneumonia, and topical antiviral therapies for upper respiratory tract infections. Ondine's technology platform is designed for straightforward clinical adoption with minimal workflow disruption and no complex compliance barriers. Note: Products are not currently for sale in the United States. The company operates as a specialized biomedical device and therapeutic solutions provider focused on addressing antimicrobial resistance through innovative light-activated infection control mechanisms.